ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 802,800 shares, a drop of 13.5% from the March 15th total of 928,600 shares. Based on an average daily volume of 154,100 shares, the short-interest ratio is presently 5.2 days.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. grew its stake in ESSA Pharma by 46.5% in the 4th quarter. Soleus Capital Management L.P. now owns 3,869,392 shares of the company's stock worth $9,751,000 after acquiring an additional 1,228,853 shares during the period. RTW Investments LP acquired a new position in shares of ESSA Pharma in the 4th quarter valued at $15,171,000. Rock Springs Capital Management LP boosted its holdings in shares of ESSA Pharma by 2.1% in the 3rd quarter. Rock Springs Capital Management LP now owns 677,005 shares of the company's stock valued at $2,092,000 after purchasing an additional 13,688 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of ESSA Pharma by 575.8% in the 3rd quarter. Two Sigma Investments LP now owns 347,758 shares of the company's stock valued at $633,000 after purchasing an additional 296,302 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of ESSA Pharma by 570.1% in the 3rd quarter. Two Sigma Advisers LP now owns 342,400 shares of the company's stock valued at $623,000 after purchasing an additional 291,300 shares during the last quarter. 75.12% of the stock is owned by hedge funds and other institutional investors.
ESSA Pharma Stock Performance
NASDAQ:EPIX traded down $0.49 during mid-day trading on Friday, reaching $7.76. The stock had a trading volume of 16,907 shares, compared to its average volume of 60,961. The firm has a market capitalization of $343.30 million, a price-to-earnings ratio of -13.15 and a beta of 1.62. ESSA Pharma has a twelve month low of $2.56 and a twelve month high of $11.67. The business has a 50 day simple moving average of $8.94 and a 200 day simple moving average of $6.88.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its earnings results on Tuesday, February 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. As a group, sell-side analysts expect that ESSA Pharma will post -0.8 earnings per share for the current year.
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
